Related Experiment Videos

Retinopathy of prematurity in southern Finland

M Lappi1

  • 1Children's Hospital, University of Helsinki, Finland.

Insights

Retinopathy of prematurity (ROP) affects 17.4% of premature infants, especially the most immature. Cryocoagulation treatment for ROP 3 with plus disease effectively prevents blindness in these vulnerable infants.

Area of Science:

  • Ophthalmology
  • Neonatology
  • Pediatric Medicine

Background:

  • Premature infants face significant risks of vision impairment.
  • Retinopathy of prematurity (ROP) is a major cause of blindness in preterm infants.
  • Early detection and intervention are crucial for managing ROP.

Purpose of the Study:

  • To determine the incidence of ROP in a cohort of premature infants.
  • To evaluate the effectiveness of cryocoagulation treatment for severe ROP.
  • To identify risk factors associated with ROP development.

Main Methods:

  • Ophthalmological examinations were conducted on 138 premature infants born between 1989-1991.
  • Infants with ROP stage 3 and plus disease received bilateral cryocoagulation.
  • Gestational age and birth weight were recorded to assess risk factors.

Main Results:

  • Twenty-four infants (17.4%) were diagnosed with ROP.
  • ROP incidence was highest among the most immature infants (mean gestational age 27.3 weeks, mean birth weight 986g).
  • Seven infants with severe ROP received cryocoagulation, with only one case of blindness.

Conclusions:

  • ROP is a significant risk in premature infants, particularly those with very low gestational age and birth weight.
  • Cryocoagulation is an effective treatment for preventing blindness in cases of ROP 3 with plus disease.
  • Continued monitoring and timely intervention are essential for managing ROP in neonatal intensive care units.

Related Concept Videos